Keywords
Last Name

Karen R. Jacobson, MD, MPH

TitleAssistant Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionInfectious Diseases
Address771 Albany St
Boston MA 02118
Phone(617) 414-5265
ORCID ORCID Icon0000-0003-4239-3685
Other Positions
TitleAssistant Professor
InstitutionBoston University School of Public Health
DepartmentEpidemiology

 Research Expertise & Professional Interests
Dr. Karen Jacobson is an Assistant Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of drug resistant tuberculosis, including identification of social, biological, and economic determinants of and risk factors for drug resistance and approaches for improving TB outcomes in resource-limited settings. Dr. Jacobson has established a highly productive collaboration with researchers at Stellenbosch University in Cape Town, South Africa, investigating the drivers of drug resistance in the Western Cape Province of South Africa and working to identify potentially modifiable factors.

 Self-Described Keywords
  • drug resistant tuberculosis
  • global health
  • tuberculosis
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med. 2016 Sep 01; 194(5):621-30. PMID: 26910495.
    View in: PubMed
  2. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016 Mar; 54(3):727-33. PMID: 26763957.
    View in: PubMed
  3. Jacobson KR, Sabin LL. Scaling up multidrug-resistant tuberculosis care in China. Lancet Glob Health. 2015 Apr; 3(4):e183-4. PMID: 25794667.
    View in: PubMed
  4. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41. PMID: 25686144.
    View in: PubMed
  5. Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, Warren RM, Jacobson KR. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. PLoS One. 2013; 8(12):e83480. PMID: 24349518.
    View in: PubMed
  6. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014 Feb; 69(2):331-42. PMID: 24055765.
    View in: PubMed
  7. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PK, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet. 2013 Oct; 45(10):1183-9. PMID: 23995135.
    View in: PubMed
  8. Jacobson KR, Theron D, Kendall EA, Franke MF, Barnard M, van Helden PD, Victor TC, Streicher EM, Murray MB, Warren RM. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis. 2013 Feb; 56(4):503-8. PMID: 23090928.
    View in: PubMed
  9. Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis. 2012 Feb; 16(2):196-202. PMID: 22236920.
    View in: PubMed
  10. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011 Aug; 53(4):369-72. PMID: 21810750.
    View in: PubMed
  11. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010 Jul 1; 51(1):6-14. PMID: 20504231.
    View in: PubMed
  12. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2002 Jan; 34(1):52-8. PMID: 11753165.
    View in: PubMed
  13. Altemus M, Greenberg BD, Keuler D, Jacobson KR, Murphy DL. Open trial of flutamide for treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1999 Jul; 60(7):442-5. PMID: 10453797.
    View in: PubMed
  14. Altemus M, Jacobson KR, Debellis M, Kling M, Pigott T, Murphy DL, Gold PW. Normal CSF oxytocin and NPY levels in OCD. Biol Psychiatry. 1999 Apr 1; 45(7):931-3. PMID: 10202583.
    View in: PubMed
Karen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department